TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts

Synthetic agonists of Toll-like receptor 9 (TLR9), a class of agents that induce specific immune response, exhibit antitumor activity and are currently being investigated in cancer patients. Intriguingly, their mechanisms of action on tumor growth and angiogenesis are still incompletely understood....

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Damiano, Vincenzo, Caputo, Rosa, Garofalo, Sonia, Bianco, Roberto, Rosa, Roberta, Merola, Gerardina, Gelardi, Teresa, Racioppi, Luigi, Fontanini, Gabriella, De Placido, Sabino, Kandimalla, Ekambar R., Agrawal, Sudhir, Ciardiello, Fortunato, Tortora, Giampaolo
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: National Academy of Sciences 2007
Θέματα:
Biological Sciences
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1920540/
https://ncbi.nlm.nih.gov/pubmed/17636117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0705226104
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια